IV Ketamine Vs. in Esketamine for MDD TRD

Launched by GUSTAVO VAZQUEZ · Jul 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two medications, ketamine and esketamine, to see how well they work for people with severe depression who haven't found relief from traditional antidepressants. Researchers want to understand how these treatments compare, especially for adults aged 18 to 75 who are already taking other medications for their depression. Participants in the study will be those who have been diagnosed with major depressive disorder and have tried at least two different antidepressants without success.

If you or a loved one are interested in participating, it’s important to know that certain health conditions might make someone ineligible, such as having psychosis, certain personality disorders, or uncontrolled high blood pressure. Participants will receive either IV ketamine or esketamine and will be closely monitored for their responses. The study is currently recruiting, so there may be an opportunity to contribute to valuable research that could help improve treatments for severe depression.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult outpatients (18-75 years old) with unipolar depression experiencing major depressive episodes as determined by the DSM5 and characterized as MDD-TRD (diagnosed with major depressive disorder as outlined by the DSM5) and experienced at least two previous failed antidepressant treatments of adequate dose and duration for the current episode
• Exclusion Criteria:
• • Individuals with psychosis, main diagnosis of personality disorder, uncontrolled hypertension, substance abuse, currently pregnant or breastfeeding, or who had a previous negative reaction to ketamine or esketamine, were ineligible to receive IV ketamine or IN esketamine.